- The disease
- Chronic kidney disease (CKD) is a long-term condition in which the kidneys progressively lose their ability to filter waste from the blood. In a subset of patients, this loss of function is driven by kidney fibrosis, a process in which scar tissue builds up within the kidney over time. Fibrosis is considered a key contributor to CKD progression, and there are limited approved therapies specifically targeting the fibrotic process in the kidney. CKD affects a large proportion of the global population and represents a significant unmet medical need.
- What the asset is trying to do
- AD-214 is an Fc-fusion protein, meaning it combines a target-binding domain with an antibody fragment (the Fc region) to extend the molecule's time in the body and aid its manufacture. The target-binding portion of AD-214 is designed to block CXCR4, a receptor found on the surface of various cell types that is involved in signalling pathways linked to inflammation and fibrosis. By antagonising CXCR4, AD-214 aims to interfere with the cellular signals that drive scar tissue formation. This mechanism is distinct from existing supportive CKD treatments, which typically focus on blood pressure control or glucose management rather than directly targeting fibrotic signalling.
- What the trial is measuring, and why it matters
- No clinical trial in kidney fibrosis or CKD has been registered for AD-214 at this time; the programme remains at the preclinical stage. Endpoints for a future clinical trial in this setting have not been publicly disclosed. In preclinical studies, efficacy is typically assessed in animal models using measures such as kidney function markers and histological scoring of fibrosis, though the specific endpoints used in Adalta's animal model work have not been detailed in the available public disclosures.
- Efficacy benchmarks in this setting
- No clinical trial for AD-214 in CKD or kidney fibrosis has been conducted, so direct efficacy comparisons are not applicable at this stage. For context, approved therapies in CKD with a component of fibrotic or inflammatory mechanism include finerenone (Kerendia), which in the FIDELIO-DKD trial demonstrated a reduction in the composite kidney endpoint (kidney failure, sustained decrease in eGFR, or kidney death) compared with placebo in patients with CKD and type 2 diabetes (per Bakris et al, New England Journal of Medicine, 2020). Preclinical animal model data are not statistically comparable to human clinical trial outcomes, and no inference about AD-214's likely clinical performance can be drawn from its preclinical results.